Clinical trials: COVID-19; Immunity
COVID-19 Vaccines
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
The effectiveness of COVID-19 vaccines in reducing the risk of severe COVID-19 is currently demonstrated. In France, since the beginning of the vaccination campaign, 54,266,859 people have received at least one injection (ie.
- Trial name
- COVIBOOSTAnci1 (NCT05405283)
- Testing
- 2nd booster with Comirnaty® (Pfizer-BioNTech), CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
- Where
- France
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19, Microbial Colonization
Role of the Oral Microbiome & Mucosal Immunity in COVID-19 Disease
Determining whether in the mouth there are differences between the participant groups in the nature and activity of mucosal innate immunity, in immune responses to SARS-COV2 antigens, or in the oral microbiome
- Conditions
- COVID-19, Microbial Colonization, Oral Disease, Periodontal Diseases
- Trial name
- MIMSA (NCT05212766)
- Testing
- COVID infection, COVID vaccination, Oral examination
- Where
- United Kingdom
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- King's College London
SARS-CoV2 Infection
Coronavirus Pediatric Serological Study
The Coronavirus Pediatric Serological Study's aim is to provide a better insight of children's immune response after SARS-CoV-2 infection.
- Trial name
- CoPSS (NCT05128435)
- Testing
- Blood sample
- Where
- Belgium
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
COVID-19, Virus Diseases
Bacillus Calmette-guérin Vaccination to Prevent COVID-19
Based on findings of the interim analysis of the ACTIVATE study showing 53% decrease of the incidence of all new infections with BCG vaccination, a new trial is designed aiming to validate if BCG can protect against COVID-19…
- Conditions
- COVID-19, Virus Diseases, Corona Virus Infection, Coronary Heart Disease
- Trial name
- ACTIVATEII (NCT04414267)
- Testing
- BCG vaccine
- Where
- 15 sites in Greece
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Hellenic Institute for the Study of Sepsis
Covid19, SARS-CoV Infection
COVID-19 in Polish Ice Swimmers.
Ice swimming is an increasingly common phenomenon in Poland. It has been confirmed that it has a beneficial effect on health by increasing the natural non-specific immunity to infections.
- Conditions
- Covid19, SARS-CoV Infection, Resistance, Disease, Hypothermia
- Trial name
- ICE (NCT04817280)
- Testing
- Ice Swimming
- Where
- 3 sites in Poland
- Volunteers
- 2,534 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
Multiple Sclerosis, Autoimmune Blistering Disease
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision…
- Conditions
- Multiple Sclerosis, Autoimmune Blistering Disease, B-Cell Deficiency
- Trial name
- NCT05286242
- Testing
- COVID19 vaccine
- Where
- United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Yale University
Pregnancy Complications, Covid19
Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19
Vitamin D defiency during pregnancy is a major public health problem worldwide; In Spain, the average intake of vitamin D is lower than recommendations in an elevated percentage of the population, ranging from 50 to 95%…
- Trial name
- D-WOMAN (NCT04825093)
- Testing
- Vitamin D supplementation in pregnant women
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
COVID-19
A COVID-19 Symptom, Exposure and Immune Response Registry
This is a 6-month, 100% remote study that will collect a broad range of data that may provide insight into the COVID-19 global pandemic.
- Trial name
- NCT04348942
- Where
- United States
- Volunteers
- 804 people, healthy volunteers welcome
- Sponsor
- ObvioHealth
COVID-19
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for successive waves, is to better understand and diagnose the infection.
- Trial name
- COVARIANT (NCT05858502)
- Testing
- Blood sample collection, Saliva sample collection, Nasopharyngeal and nasal sample collection
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS-CoV-2, COVID-19
Vienna Versus SARS-CoV-2 Virus Study
This study examines the seroprevalence against SARS-CoV-2 in health care workers and patients at the Vienna General Hospital.
- Trial name
- VIVI (NCT04407429)
- Testing
- Laboratory Analyses
- Where
- Austria
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
COVID-19
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
This is a study to evaluate the ability of UB-612 vaccine to boost immunity of subjects who previously received two doses of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses.
- Trial name
- NCT05167253
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
COVID-19, Serology
Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms
Three hundred healthcare workers with mild symptoms for Covid-19 will be followed during three months. Each two weeks, serological tests will be performed. Re-infection will be monitored by saliva-swabs.
- Trial name
- NCT04356586
- Where
- Belgium
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Sciensano
Vaccine Adverse Reaction, COVID-19
Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.
Background: Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-COV2 vaccines.
- Conditions
- Vaccine Adverse Reaction, COVID-19, Vaccine Reaction
- Trial name
- NCT05228912
- Testing
- COVID-19 Vaccines
- Where
- Mexico
- Volunteers
- 1,870 people, healthy volunteers welcome
- Sponsor
- Hospital Clinica Nova
COVID-19
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
Background: People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital.
- Trial name
- NCT04362865
- Where
- 4 sites in United States
- Volunteers
- 679 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
SARS CoV 2 Infection
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
This is a Phase II study with single-blinded safety phase followed by double-blinded randomization, placebo-controlled, of administration of a single dose by two different administration routes (intramuscular route or intranasal…
- Trial name
- NCT05205746
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- 4 sites in Mexico
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
COVID-19
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
This is an experimental study without drug and device, non-profit, single-center. The general objective of the project is to study how the adaptive immune response evolves against SARS-CoV-2 with repeated vaccination boosters and…
- Trial name
- COVaxFragile (NCT06300853)
- Testing
- Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses
- Where
- Italy
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
COVID - 19
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration…
- Trial name
- NCT06831786
- Testing
- Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
Immunology, Allergy
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections.
- Conditions
- Immunology, Allergy, Genetic Diseases, Infectious Diseases
- Trial name
- COVIFERON (NCT06762002)
- Testing
- blood sample
- Where
- 9 sites in France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Humoral Immunity
Humoral Immunity Study After a Booster Dose of Soberana Plus (FINLAY-FR-1A) Vaccine Against COVID-19
To evaluate the dynamics of IgG levels to the SARS-CoV-2 virus after a booster dose of Soberana Plus vaccine.
- Trial name
- NCT05689177
- Testing
- Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)
- Where
- Belarus
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gomel State Medical University